The goal of the Pediatric Malignancies Program (Program) is to improve, the outcome for children with cancer through basic and clinical translational research. Pediatric cancers are unique in their morphology, tissues of origin, and behavior. They provide an opportunity to understand the link between normal development and the aberrant signaling networks of childhood malignancy;to discover through these genetic networks new therapeutic targets;and then integrate these into innovative clinical trials. The molecular studies will also lead to new understanding of the interactions of genetics and environment in cancer development and the late effects of treatment, thus improving the outcome for survivors of pediatric cancer. Our integrated research program provides a forum through which insights into childhood cancer can inform trainees, health care professionals, patients and the public. The main research themes of the Program focus particularly on the common childhood tumors, neuroblastoma, brain tumors, leukemias, and sarcomas;and translating our molecular and genomic studies into developmental therapeutics in these cancers (prioritizing PISK, RAS and MAPK signaling as areas where we have strong collective expertise), and understanding the late effects and epidemiology of childhood cancer in order to improve survival and quality of life. The Program has 18 members from six different departments. The Program is enhanced by close synergy with Helen Diller Family Comprehensive Cancer Center (Center) Programs such as Hematopoietic Malignancies, Neurologic Oncology, Developmental Therapeutics, Cancer Disparities, and Tobacco Control, as well as many interactions with scientists in basic science programs, such as Cancer Genetics and Cancer, Immunity, and the Microenvironment, and with essential use of the Center Cores such as Clinical Research Support Office, Laboratory for Cell Analysis, Preclinical Therapeutics, and Genome Analysis. The Program has $8,789,236 total peer reviewed support for the last budget year. The Program has 20% intra-programmatic and 36% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-15
Application #
8567882
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2013
Total Cost
$96,543
Indirect Cost
$90,775
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREā„¢). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49

Showing the most recent 10 out of 192 publications